Myomo Posts Record $11.4M Revenue, Net Loss Widens to $3.8M
Myomo reported a Q4 2025 net loss of $3.8 million, compared with a $0.3 million loss a year earlier, with adjusted EBITDA turning negative. Revenue hit a record $11.4 million, driven by 46% quarterly and 48% annual international gains exceeding $2 million, and management projects 2026 revenue of $43–$46 million.
1. Q4 Financial Results
Myomo’s Q4 2025 net loss widened to $3.8 million from $0.3 million in the prior year period, and adjusted EBITDA turned negative as expenses rose.
2. Revenue Drivers and International Growth
The company achieved its highest quarterly revenue of $11.4 million, with international operations surpassing $2 million for the first time and growing 46% sequentially and 48% year-over-year.
3. 2026 Guidance and Outlook
Management projected 2026 revenue between $43 million and $46 million, aiming to leverage growth in the orthotics and prosthetics channel and recurring patient sources to improve operating leverage.
4. Strategic Initiatives and Market Expansion
To reduce rising marketing costs, Myomo hired a new head of marketing and engaged a digital agency; it plans to train 200 clinics by 2028, expand national O&P programs, and use a University of Utah study to support insurance coverage expansion.